InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of InflaRx N.V. (NASDAQ:IFRX) have earned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and two have given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $7.00.

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday, June 24th. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. HC Wainwright raised their price objective on InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Guggenheim restated a “buy” rating and set a $14.00 price objective on shares of InflaRx in a report on Tuesday, April 21st. Finally, Oppenheimer assumed coverage on InflaRx in a research report on Friday, April 24th. They issued an “outperform” rating and a $5.00 price objective for the company.

Institutional Trading of InflaRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE acquired a new position in shares of InflaRx during the 3rd quarter valued at about $3,316,000. Suvretta Capital Management LLC grew its holdings in InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after purchasing an additional 1,450,000 shares during the period. 683 Capital Management LLC increased its position in InflaRx by 47.3% during the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock worth $3,348,000 after purchasing an additional 1,065,000 shares during the last quarter. Woodline Partners LP acquired a new position in InflaRx during the first quarter worth approximately $766,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in InflaRx during the second quarter worth approximately $262,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

InflaRx Trading Down 2.4%

NASDAQ:IFRX opened at $1.65 on Thursday. InflaRx has a 12-month low of $0.74 and a 12-month high of $2.95. The firm has a market cap of $119.28 million, a price-to-earnings ratio of -2.32 and a beta of 2.44. The company’s 50-day moving average is $2.00 and its two-hundred day moving average is $1.50.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. On average, equities research analysts forecast that InflaRx will post -0.29 earnings per share for the current fiscal year.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.